Email this article COMBINATION NEOADJUVANT THERMOCHEMICAL THERAPY IN PATIENTS WITH RECTAL CANCER
- Authors: Barsukov Y.A.1, Kuzmichev D.V.1, Tkachev S.I.1, Aliev V.A.1, Tamrazov R.I.1, Malikhov A.G.1, Mamedli Z.Z.1, Tataev I.S.1, Vlasov O.A.1, Gordeev S.S.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: Vol 3, No 3 (2014)
- Pages: 23-28
- Section: ORIGINAL REPORTS
- Published: 28.02.2015
- URL: https://onco-surgery.info/jour/article/view/76
- DOI: https://doi.org/10.17650/2220-3478-2014-0-3-23-28
- ID: 76
Cite item
Full Text
Abstract
A new combined treatment scheme with short-course chemoradiotherapy and 2 selective radiosensitizers (metronidazole in a polymeric composition and local hyperthermia) is investigated in this article.
Material and methods. 77 T1–3N0–2M0 rectal cancer patients treatment data was analyzed. All patients received 5 Ч 5 Gy radiotherapy with capecitabine 1300 mg/m2 days 1–5 per os and radiosensitization with local hyperthermia and metronidazole.
Results. Investigated treatment scheme has acceptable toxicity and leads to high local control rate (none of the patients experienced local recurrence). 7 (9.1 %) patients developed distant metastases. 59 (76.6 %) patients had sphincter-sparing surgery. Median followup was 65.6 months. 5-year survival rate was 81.7 %.
Conclusion. Developed treatment scheme is safe and leads to high local control rate.
About the authors
Yu. A. Barsukov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: ss@oncoproct.ru
Russian Federation
D. V. Kuzmichev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: ss@oncoproct.ru
Russian Federation
S. I. Tkachev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: ss@oncoproct.ru
Russian Federation
V. A. Aliev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: ss@oncoproct.ru
Russian Federation
R. I. Tamrazov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: ss@oncoproct.ru
Russian Federation
A. G. Malikhov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: ss@oncoproct.ru
Russian Federation
Z. Z. Mamedli
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: ss@oncoproct.ru
Russian Federation
I. Sh. Tataev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: ss@oncoproct.ru
Russian Federation
O. A. Vlasov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: ss@oncoproct.ru
Russian Federation
S. S. Gordeev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: ss@oncoproct.ru
Russian Federation
References
Supplementary files
